Harmony Biosciences Holdings, Inc.
HRMY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.75 | -0.51 | 0.04 | -0.46 |
| FCF Yield | 11.17% | 11.40% | 4.43% | 4.01% |
| EV / EBITDA | 7.22 | 8.14 | 21.85 | 30.01 |
| Quality | ||||
| ROIC | 17.20% | 21.53% | 34.90% | 21.12% |
| Gross Margin | 78.06% | 79.17% | 80.93% | 81.82% |
| Cash Conversion Ratio | 1.51 | 1.70 | 0.80 | 2.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.74% | 23.98% | 39.95% | 270.72% |
| Free Cash Flow Growth | -0.19% | 51.83% | 46.85% | 2,070.30% |
| Safety | ||||
| Net Debt / EBITDA | -1.16 | -0.53 | -0.35 | -0.48 |
| Interest Coverage | 10.91 | 8.08 | 6.39 | 3.62 |
| Efficiency | ||||
| Inventory Turnover | 21.79 | 22.61 | 19.43 | 12.53 |
| Cash Conversion Cycle | 27.17 | 9.26 | 47.87 | 64.19 |